BiotechTube

Decitabine

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndrome

Conditions

Myelodysplastic Syndrome

Trial Timeline

Aug 1, 2008 → Aug 1, 2012

NCT ID
NCT00744757

About Decitabine

Decitabine is a phase 2 stage product being developed by Johnson & Johnson for Myelodysplastic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00744757. Target conditions include Myelodysplastic Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT01333449Phase 2Terminated
NCT00744757Phase 2Completed

Competing Products

20 competing products in Myelodysplastic Syndrome

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
28
JSP191Jasper TherapeuticsPhase 1
25
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
25
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
33
Erlotinib HydrochlorideAstellas PharmaPhase 2
52
Decitabine + Decitabine + DecitabineEisaiPhase 2
52
Decitabine + Valproic AcidEisaiPhase 2
52
decitabine + decitabineEisaiPhase 2
52
decitabine + azacitidineEisaiApproved
85
DecitabineEisaiPhase 2
52
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
33
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
52
Subcutaneous DecitabineEisaiPhase 1
33
DecitabineEisaiPhase 2
52
Galunisertib + PlaceboEli LillyPhase 2/3
65
DSP-7888Sumitomo PharmaPhase 1/2
41
TP-0184Sumitomo PharmaPhase 1/2
41
Epoetin alfaJohnson & JohnsonPhase 2
52
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
52
DecitabineJohnson & JohnsonPhase 2
52

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85